Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 20, Issue 9, Pages 1099-1108Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.2016.1164693
Keywords
MicroRNA; miRNA; miRNA inhibitors; miR-221; miR-221/222; oligonucleotidebased therapy; cancer; myeloma
Categories
Funding
- AIRC (the Italian Association for Cancer Research) [9980]
Ask authors/readers for more resources
Introduction: MicroRNAs (miRNAs) are key non-coding RNA post-transcriptional regulators of messenger RNAs (mRNAs), and are deeply dysregulated in human cancer. A rising body of evidence indicates that miRNAs represent valuable therapeutic targets. In this light, the cluster miR-221/222 are of particular relevance, given that they are strongly upregulated in a variety of solid and hematologic malignancies. Area covered: This review summarizes recent findings on the roles played by miR-221/222 in human cancer and their potential clinical value as promising targets for therapeutic studies. Expert opinion: The rising body of advanced preclinical evidence on the biological significance of miR-221/222 in a variety of malignancies indicates that they will play a crucial role in the future of innovative therapeutic strategies, both as validated biomarkers and targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available